From avoiding digital health failure to BIO 2015: 5 must-read stories from MedCity News this week
Check out a recap of the BIO and Health Innovation conferences from MedHeads and other top stories from this week.
presented by
#BIO2015: What life sciences sectors are ripe for M&A?
Life sciences M&A remains bullish - 2015 will likely outpace 2014 in terms of deals. But which sectors are most lucrative? CNS, pain and women's health, a new report from Campbell Alliance finds.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
New institute refines hackathon concepts for business
The Hacking Medicine Institute is rejiggering hackathon concepts so they're applicable to the business of healthcare. But in some ways, it's the anti-hackathon. "At MIT, we love technology," said Ayesha Khalid, co-founder of the Institute. "But I don't think the solution here is more technology."
Eric Topol: Frustrated that doctors are slow to adopt pharmacogenomics
"We basically have a medical community that doesn't embrace the use of genomics," Dr. Eric Topol said. "Often times these days, it's the patients that are clamoring."
Topol: Clinical trials offer exciting examples of convergence of digital health and drug development
Dr. Eric Topol said, "When I wrote 'Creative Destruction of Medicine' four years ago there was zero convergence...Now there are so many examples."
#BIO2015: BIO’s now “Biotechnology Innovation Organization” (Groan)
Can we think of a less innovative word these days than "innovative?" BIO doesn't seem to care, given its hackneyed new name change.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
#BIO2015: Nanomedicine… the next big thing?
Nanomedicine is emerging in the life sciences as a potent way to enhance drug performance - but the applications don't stop there, according to a panel of proponents speaking at BIO.
#BIO2015: The digital disruptors are making their mark in healthcare
Digital health has the potential to make healthcare delivery more efficient but it will be an occasionally uncomfortable transformation with plenty of push back.
#BIO2015: Improving basic science research with a translational model
A new Battelle report examines new trends in translational science among academia-industry collaboration, and the impact it has on basic science research.
#BIO2015: Open-source biopharma R&D improves late-stage success
Collaboration, even with competitors, helps usher a drug into successful development, a new report from Deloitte released at this week's BIO convention says.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
#BIO2015: Are venture capitalists too focused on the science?
Vertex Pharmaceuticals founder Joshua Boger says that venture capitalists have too much of a say in how to shape a startup - when really, it should be left up to a solid team of scientists.